New Delhi: The All India Institute of Medical Sciences (AIIMS), New Delhi, has initiated the GRASSROOT (Gravity Stent-Retriever System for Reperfusion of Large Vessel Occlusion Stroke Trial) clinical trial, testing a next-generation stent-retriever for stroke treatment tailored to the unique characteristics of stroke clots prevalent in the Indian population.
"We are eager to evaluate this advanced technology, given India’s unmet needs in stroke treatment," stated Dr. Shailesh Gaikwad, Professor and Head of Neuroimaging & Interventional Neuroradiology at AIIMS. "Our goal is to improve stroke outcomes and establish new standards in stroke care globally."
This innovative stent retriever, developed with input from both international and Indian experts, aims to restore blood flow to the brain swiftly, safely, and completely. It also offers a cost-effective solution, expanding access to life-saving treatment across India and worldwide.
Launched on August 15, 2024, the trial marks a significant advancement in stroke care in India. The first patient treated at AIIMS under Dr. Gaikwad and Dr. Deepti Vibha’s leadership has successfully recovered and was discharged. Dr. Vibha expressed optimism, saying, "The GRASSROOT trial is set to revolutionize stroke care in India and beyond."
India faces a critical challenge in stroke care, with only 4,500 out of 375,000 eligible stroke patients receiving life-saving mechanical thrombectomy annually. Dr. Shashvat Desai, Chief of R&D at Gravity, emphasized the importance of prioritizing stroke care to harness India’s demographic dividend.
The GRASSROOT trial spans 16 hospitals across India, including AIIMS and JIPMER, Pondicherry. Dr. Kalpesh Shah, a leading neurosurgeon at Zydus Hospital, Ahmedabad, who recently used the new stent-retriever, remarked, "These innovative devices will transform global access to safe and effective stroke care."
You may like also
tn health to begin round 2 pg medical counselling 2024 check tentative schedule
